Cellbion Co., Ltd
Cellbion is a KOSDAQ-listed (308430) radiopharmaceutical developer based in Seoul. It has submitted a conditional marketing application in South Korea for its prostate-cancer radioligand Lu-177-DGUL, and its Phase 3 plan has been approved by the MFDS.
| Headquarters | Seoul, South Korea |
|---|---|
| Listing | KOSDAQ:308430 |
| Lead asset / stage | Lu-177-DGUL Conditional marketing application submitted — South Korea |
| Latest event | Cellbion disclosed MFDS approval of the Phase 3 Lu-177-DGUL clinical trial plan. |